Further studies are essential for the development of GDF11‐ and other metabotrophins‐based systemic therapies for obesity and related cardio‐ and neurometabolic diseases, including Alzheimer's disease.1, 3. The gene discussed is GDF11; the disease is Alzheimer disease.